Spots Global Cancer Trial Database for A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
Official Title: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
Study ID: NCT04702737
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Mayo Clinic Arizona, Phoenix, Arizona, United States
University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
University of Chicago, Chicago, Illinois, United States
Community Health Network MD Anderson Cancer Center - North, Indianapolis, Indiana, United States
Washington University, Saint Louis, Missouri, United States
Weill Cornell Medical College, New York, New York, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
The Ohio State University, Columbus, Ohio, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Medizinische Universitaet Graz, Graz, , Austria
Ordensklinikum Linz Elisabethinen, Linz, , Austria
Landeskrankenhaus Salzburg, Salzburg, , Austria
Universitair Ziekenhuis Gent, Gent, , Belgium
Gustave Roussy, Villejuif Cedex, , France
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Erasmus Medisch Centrum, Rotterdam, , Netherlands
Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña, Spain
Royal Marsden Hospital, Sutton, , United Kingdom
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
